A recent study found over 18% of patients with relapsed or refractory multiple myeloma treated with a proteasome inhibitor were faced with cardiovascular adverse events.

News

The International Myeloma Foundation (IMF)–the oldest and largest organization dedicated to improving the lives of myeloma patients while working toward a cure–has issued a statement calling a report by the Institute for Clinical and Economic Review (ICER) on the value of myeloma drugs overly simplistic and one that could limit patient access to optimal treatments.

Read More

Combination therapy involving a novel treatment is associated with reduced risk of death and improved progression-free survival (PFS) in patients with advanced multiple myeloma, according to research presented at the 22nd Congress of the European Hematology Association (June 22-25, 2017; Madrid, Spain).

-----

Related Content

Read More

Multiple prognostic tools help risk stratify older patients with multiple myeloma and predict treatment-specific survival, according to data that will be presented at the 22nd Congress of the European Hematology Association (June 22-25, 2017; Madrid, Spain).

-----

Related Content

Read More

Adding a targeting agent to standard of care carfilzomib, lenalidomide, and dexamethasone (KRd) for multiple myeloma is a safe and efficacious alternative to autologous stem cell transplantation (ASCT) with KRd, according to research presented at the 2017 ASCO Annual Meeting (June2-6, 2017; Chicago, IL).

-----

Related Content

Read More

Subscribe to Multiple Myeloma